The first contract lost 12000 yuan! N Weijie fell more than 30% on the first day. How to find a big meat label?

Today (April 12), the three major indexes rose sharply in the afternoon. As of the close, the Shenzhen Composite Index and the gem index both rose by more than 2%. However, the performance of new shares listed today was poor. N Haichuang (Haichuang pharmaceutical) and N Weijie (Weijie Chuang core) fell by nearly 29.9% and 36% respectively, while n Ruide (Ruide intelligent) was the only one to be popular, with an increase of nearly 5%.

n Weijie Yizhang lost more than 10000 yuan, and the performance of new shares today was poor

Weijie Chuangxin is mainly engaged in RF front-end chips. The funds raised this time are mainly used for IC production and testing, R & D center construction projects and supplementary working capital. In terms of performance, the company expects to turn losses into profits in the first quarter of this year, mainly due to the improvement of gross profit margin year-on-year. The company landed on the science and innovation board today, with an issue price of 66.6 yuan, an issue market sales ratio of 14.72 times and an industry P / E ratio of 41.46 times. Due to the high issue price and the poor overall market sentiment, Weijie Chuangxin fell 36.04% on the first day. Based on the 500 shares in the first signing, the loss amounted to 12000 yuan.

Haichuang pharmaceutical is a technology platform based on deuterated technology and protac targeted protein degradation. According to the prospectus, the company’s core products are still in the clinical stage, the company has not yet made a profit and is expected to continue to lose money, and still needs to continue to invest in the research and development of pipeline under research on a large scale. The company said that it may be difficult to achieve profit and loss balance in a period of time. The company also landed on the science and innovation board today, with an issue price of 42.92 yuan, an issue market research ratio of 9.91 times and an industry P / E ratio of 35.71 times. After today’s opening, Haichuang pharmaceutical continued to decline, and the decline finally closed at 29.87%. If calculated by 500 shares in the first signing, the loss reached 6410 yuan.

The two new shares listed on the science and Innovation Board fell sharply today, while the new shares landing on the gem, red intelligence, had a slightly better scenery. Red intelligence made a short break at the opening today, but then gradually strengthened, rising by 5% as of the closing. If it is calculated based on 500 shares in the first signing, it can make a profit of nearly 800 yuan. The company’s main business is intelligent controller. Its issuing price is 31.98 yuan and the issuing P / E ratio is 49.77 times, slightly higher than the industry P / E ratio of 41.75 times. In terms of performance, the company expects that the revenue in the first quarter is flat year-on-year, and the deduction of non net profit decreased by 28.06% year-on-year, mainly due to the rise of raw material prices, but the price transmission has a certain lag.

new shares soared on the first day, focusing on the structural opportunities of individual stocks

Recently, the breaking rate of new shares soared again. According to the performance of new shares in recent two weeks (from March 28 to April 12), 9 of the 15 new shares listed broke on the first day, accounting for nearly 60%. The performance of new shares on the science and Innovation Board was particularly poor. Among the seven new shares, only Zhongfu Shenying rose on the first day, and the other stocks fell to varying degrees. Among them, Weijie Chuangxin and Puyuan Jingdian listed today both fell by more than 30% on the first day Shanxi Securities Co.Ltd(002500) believes that since late March, the near end new shares have continued to cool down, and there are signs of acceleration this week, market style change, high opening valuation of new shares, decline of overall valuation center and other factors jointly cause the above phenomenon.

Huajin securities also pointed out that under the background of relatively low overall market risk preference and more obvious investment preference turning to “steady growth”, although the current IPO pricing is somewhat flat compared with the peak period, it has failed to show a higher valuation cost performance than comparable companies in the secondary market , the overall performance of the IPO sector is flat, and it is mainly based on individual stock structural opportunities. In the short term, considering that there are some new shares with relatively low absolute P / E ratio in the batch of new shares that have been subscribed but not yet listed, the performance of new shares may be improved

For the investment in the secondary market of new shares, Huajin Securities said that it tends to look at the possible structural opportunities from three dimensions: first, the high growth new shares catalyzed by the disclosure of relevant performance in the quarter of annual report; Second, new shares of catalyzed by the concept of “steady growth”, such as infrastructure industry chain related and inflation benefit and other new shares; Third, the rebound momentum of newly listed new shares that may exist due to emotional changes is poised .

- Advertisment -